logo-loader
viewBioSig Technologies, Inc.

BioSig Technologies subsidiary partners with contract R&D company to evaluate its drug merimepodib as a coronavirus treatment

The parties plan to evaluate the drug as a standalone treatment and in combination with other antiviral agents or immune modulators

Coronavirus graphic
Merimepodib is intended to be orally administered and has demonstrated broad-spectrum in vitro antiviral activity, including strong activity against SARS-CoV-2 in cell cultures

BioSig Technologies Inc (NASDAQ:BSGM) and its subsidiary ViralClear Pharmaceuticals Inc announced a partnership Thursday with contract R&D and manufacturing company Albany Molecular Research Inc (AMRI) to investigate its drug merimepodib to fight SARS-CoV-2, the virus that causes Covid-19.

The parties plan to evaluate the drug as a standalone treatment and in combination with other antiviral agents or immune modulators. 

“As part of our ongoing development and commercialization strategy we are delighted to be working with AMRI as our second US-based active pharmaceutical ingredient (API) supplier,” ViralClear CEO Steve King said in a statement. “The rapid transfer, scale up and validation of merimepodib API manufacture is key to our future supply chain and commercialization strategy. ViralClear is committed to using US-based CDMOs for the development and commercialization of merimepodib.”

WATCH: BioSig Technologies to begin first-in-human studies of its PURE EP System at the Mayo Clinic

Merimepodib is intended to be orally administered and has demonstrated broad-spectrum in vitro antiviral activity, including strong activity against SARS-CoV-2 in cell cultures, the company said. The drug was originally being developed as a treatment for chronic hepatitis C and psoriasis by Vertex Pharmaceuticals Inc.

“AMRI is proud to partner with ViralClear in this vital effort of seeking a potential treatment for COVID-19,” AMRI President Christopher Conway said. “Our team is committed to applying the expertise and experience we’re renowned for to help combat this complex global health challenge.”

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: BioSig Technologies, Inc.

Price: 7.43 USD

NASDAQ:BSGM
Market: NASDAQ
Market Cap: $210.59 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of BioSig Technologies, Inc. named herein, including the promotion by the Company of BioSig Technologies, Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

BioSig Technologies forms Scientific Advisory Board by adding industry veterans

BioSig Technologies Inc (NASDAQ:BSGM) CEO Kenneth Londoner tells Proactive its subsidiary ViralClear Pharmaceuticals Inc has formed its Scientific Advisory Board with two industry veterans experienced as both regulators and corporate executives. Londoner adds what's more, the group adopted a...

2 weeks, 6 days ago

2 min read